The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
Key facts
- Where
- Arnhem and Tilburg, NetherlandsSee the 2 sites
Where in Netherlands
- Rijnstate HospitalArnhem, NetherlandsContact: Michel Reijnen, MDTaking people
- Stichting Elisabeth-TweeSteden ZiekenhuisTilburg, NetherlandsContact: Jan Heyligers, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- W.L.Gore & Associates
- Trial code
- NCT05811364
- Record updated
- 13 May 2026
- Original description
The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.Read full original descriptionShow less
The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.
Inclusion: Age ≥ 18 years at time of informed consent signature; Informed Consent Form (ICF) is signed by the subject; Subject can comply with protocol requirements, including follow-up; Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5); Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies); Patient has: Unilateral or bilateral single or multiple lesions (>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length; Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm; Patient has a sufficient (<50% stenotic) common femoral artery and at least one sufficient (<50% stenotic) femoral artery (deep or superficial); Patient has at least one sufficient (<50% stenotic) infrapopliteal run-off vessel.
Exclusion: Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use; Patient has previous stenting in the iliac arteries; Patient has previous surgical bypass in the target limb; Patient is currently participating in another investigative clinical study unless received written approval by the sponsor; Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery; Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery); Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization); Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin); Patient has evidence of a systemic infection; Patient has severe chronic renal insufficiency (serum creatinine level > 2.5mg/dL) and not undergoing hemodialysis; Life expectancy <1 year; Patient is pregnant at time of informed consent; Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure); Patient has an abdominal aortic artery lesion or aneurysm; Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament.